Babak Bamdad is a respected presence in the New York community who leads the pharmacy department at Lincoln Hospital as director and chief. Supervising operations, Babak Bamdad strives to maintain high levels of department efficiency while complying with federal regulatory mandates. Active with professional organizations, he maintains a strong interest in developments in the pharmaceutical industry.
A recent Business Insider article discussed what is described as the first positive Alzheimer's trial in several years. As presented at the Alzheimer's Association International Conference, Biogen and Eisai completed a phase 2 study for the drug BAN2401 encompassing 800 early Alzheimer's disease patients. The approach involves targeting the beta amyloid proteins that accumulate in brains of those with Alzheimer's disease.
The trial results were a 30 percent reduction of beta amyloid proteins among patients who took the highest dose of BAN2401, as opposed to those receiving placebos. With PET imaging employed in identifying amyloid plaques within the brain, 81 percent of patients taking high doses of BAN2401 improved from amyloid positive to amyloid negative over an 18 month period. With a major clinical milestone achieved, further trials of this novel therapeutic approach are expected to continue.
At Lincoln Medical and Mental Health Center, Babak Bamdad’s primary duties involve establishing and maintaining quality, performance, and productivity standards in accordance with those set by Presentation Medical Center.